The text starts here.

News Release

FOR IMMEDIATE RELEASE
March 30, 2016

Notification Regarding Revision of Consolidated Financial Results Forecasts (IFRS) for the Fiscal Year Ending March 31, 2016

Listed Company Name: Eisai Co., Ltd.
Representative: Haruo Naito
Representative Corporate
Officer and CEO
Securities Code: 4523
Stock Exchange Listings: First Section of the Tokyo
Stock Exchange
Inquiries: Sayoko Sasaki
Vice President, Corporate Affairs
Phone +81-3-3817-5120

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that based on recent trends in business results, etc., the company has revised its full-year consolidated financial results forecasts for the fiscal year ending March 31, 2016 (April 1, 2015 to March 31, 2016) previously announced on February 2, 2016, as follows:

1.  Revised full-year consolidated financial results forecasts for the fiscal year ending March 31, 2016 (April 1, 2015 to March 31, 2016)
(Unit: Millions of yen, unless otherwise noted.)
  Revenue Operating
profit
Profit before
income taxes
Profit for
the period
Basic
earnings
per share
Previously announced forecast (A)
(Feb. 2, 2016)
556,500 51,000 49,000 37,000 129.00 yen
Currently revised forecast (B) 547,000 51,000 49,000 50,000 174.28 yen
Change in amount (B - A) -9,500 13,000  
Percentage of change (%) -1.7% –% –% 35.1%  
(Reference) Business results for the fiscal year ended March 31, 2015 548,465 28,338 25,875 43,453 151.57 yen

2.  Reason for revision of the consolidated financial results forecasts
  Revenue is forecasted to be ¥547,000 million (down 0.3% from the previous fiscal year) due to the impact of the latest results of the Japan pharmaceutical business and exchange rates.
  Operating profit is forecasted to be ¥51,000 million which is unchanged from the previous forecast as the impact from the decrease in revenue will be offset by further progress in cost optimization.
  Profit for the period is forecasted to be ¥50,000 million (up ¥13,000 million from the previous forecast), attributable to the transfer of shares in AkaRx Inc. by Eisai's U.S. subsidiary Eisai Inc. as announced today. Furthermore, Eisai intends to set the dividend for the period (second six-month period ending March 31, 2016) at ¥80 per share, with the forecast for the total dividend for the year remaining unchanged at ¥150 per share (same amount as the previous fiscal year).

*Please note that actual business results may change due to several factors since the above-mentioned forecasts were made based on information available as of March 30, 2016.

***